C-DIMs inhibit ER-negative MDA-MB-231 and MDA-MB-453 breast cancer cell proliferation and tumor growth in athymic nude mice bearing MDA-MB-231 cells as xenografts. C-DIMs represent a novel series of compounds that exert their growth inhibitory and antitumorigenic effects in a cell context-dependent manner. C-DIMs activate PPARγ in a number of cancer cell types including ovarian, bladder, colon, pancreatic and ER-negative and ER-positive breast cancer cells [
19-
22,
24,
25]. PPARγ agonists inhibit cancer growth by molecular mechanisms that include G
1 cell cycle arrest, induction of apoptosis and terminal differentiation [
43-
46]. PPARγ-active C-DIMs and other PPARγ agonists also activate PPARγ-independent growth inhibitory pathways including induction of NAG-1, ER stress and apoptosis [
20,
47-
52]. C-DIMs induce NAG-1 which is proapoptotic in some cancer cell lines; however, in MDA-MB-231 and MDA-MB-453 cells, these compounds induced NAG-1 but not apoptosis. In addition, induction of other receptor-dependent and -independent pro-apoptotic and differentiation pathways such as ER stress and caveolin 1 was not observed in ER-negative breast cancer cells. Thus, the precise mechanism of C-DIM-induced cell death in ER-negative breast cancer cells is unclear and multiple pathways may be involved.
EB1089 is a vitamin D analog that induces caspase-independent cell death in ER-positive MCF-7 and ER-negative MDA-MB-231 and MDA-MB-453 breast cancer cells, and similar results were observed for C-DIMs which also induced caspase-independent growth inhibition which could not be reversed after co-treatment with the pan-caspase inhibitor zVAD-fmk (Figure ). We also confirmed that treatment with C-DIMs for 48 h did not induce Annexin V staining indicative of early apoptotic cells in ER-negative breast cancer cells, whereas the pro-apoptotic agent MG132 induced cells staining with Annexin V staining in cells (Figure ). These results coupled with previous studies showing that treatment with C-DIMs for 24 h did not induce caspase-dependent PARP cleavage in these cell lines [
26] confirm that these compounds primarily induce apoptosis-independent cell death. Other chemotherapeutic agents such as the cytotoxic drug paclitaxel and related analogs induced cell death in breast cancer cells; however, only a small percentage of cells were undergoing apoptosis [
29]. Thus, the current studies suggest that an alternative form of cell death is induced by C-DIMs in ER-negative breast cancer cells and this contrasts with the induction of caspase-dependent apoptosis in ER-positive MCF-7 cells treated with C-DIMs [
25].
Necrosis is an alternative form of cell death and although initially considered an uncontrolled form of cell demise, there is increasing evidence supporting the concept of programmed necrosis [
53]. For instance, DNA damaging agents induced programmed cell death in Bax
-/-Bak
-/- cells but only in actively proliferating cells and these observations suggested an intrinsic cellular control point that decides cellular fate [
54]. This form of cell death is particularly appealing for chemotherapeutic agents since many tumor cells have dysfunctional apoptotic pathways and, therefore, apoptosis-inducing agents are not always effective for treating cancer [
53]. In MDA-MB-231 cells, minimal staining of PI and a statistically significant release of LDH was observed only after treatment with DIM-C-pPhCF
3; signs of necrosis (PI staining) were also observed in MDA-MB-231 cells treated with DIM-C-pPhtBu or DIM-C-pPhC
6H
5 (Figure and ). The lack of LDH release and PI staining in MDA-MB-453 cells treated with C-DIMs (Figure and ) suggested that necrosis was not significantly induced in this cell line. These results also indicate some structure-dependent differences between C-DIMs and also with the structurally-related ring-substituted DIMs. For example, 5,5'-dibromoDIM induced necrotic cell death in ER-negative MDA-MB-453 cells, whereas DIM-C-pPhtBu and DIM-C-pPhC
6H
5 did not activate this cell death pathway [
12].
Autophagic cell death is an alternative form of programmed cell death where cells lack the hallmarks of apoptosis but there is an accumulation of autophagic vacuoles in the cytoplasm [
55], and several structurally diverse chemotherapeutic agents induce autophagic cell death in various cancer cell lines [
28-
30,
32-
34]. For example, the PPARγ agonist prostaglandin J2 induced autophagic cell death in prostate cancer cells [
34] and the phytochemical sulforaphane induced autophagic cell death in prostate cancer cells [
28]. Therefore, we also examined the effects of C-DIMs on activation of autophagy in MDA-MB-231 and MDA-MB-453 breast cancer cells. There are several biochemical methods for detecting autophagic activity including acidic dyes that label vacuoles which exhibit lysosomal activity [
27]. Autophagic cell death in prostate cancer cells treated with sulforaphane exhibited lysosomotropic staining of cytoplasmic vacuoles with acridine orange [
28]. Other chemotherapeutic candidate drugs induce signs of autophagy in breast cancer cells [
29,
32,
37,
56]. Prenylated flavones inhibited cell growth and induced autophagy in both ER-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells and this response was typified by the formation of cytoplasmic vacuoles that stained with the autophagic marker MDC [
56]. The vitamin D analog EB1089 also inhibited cell growth in MCF-7 breast cancer cells and increased uptake of MDC into cytoplasmic vacuoles [
37]. These observations were similar to effects of C-DIMs on ER-negative breast cancer cells which also exhibited increased uptake of MDC into vacuoles (Figure ), suggesting that these compounds induce autophagy. Therapeutic agents such as EB1089 and prenylated flavones typically induce punctate lysosomotropic staining, whereas treatment with DIM-C-pPhtBu in particular induced formation of very large MDC-stained vacuoles (Figure ). These differences in staining may be due, in part, to differences in the size of autophagosomes in various cancer cell lines [
57] caused by differences in autophagic flux.
LC3b, a critical protein involved in the early stage of autophagosome formation, becomes lipidated upon induction of autophagy [
58]. Induction of LC3-II protein expression, an increase in the ratio of LC3b-II/LC3b-I expression, and translocation of LC3 to autophagosomal membranes are diagnostic molecular markers indicative of autophagy [
39]. For example, treatment of breast cancer cells with camptothecin or paclitaxel analogs increase the ratio of LC3b-II/LC3b-I protein expression [
29,
59]. With the exception of DIM-C-p-PhCF
3 in MDA-MB-453 cells, treatment with C-DIMs induced translocation of GFP-LC3 from the cytoplasm to autophagosomal membranes (Figure and ). Chemotherapeutic agent EB1089 or radiation that induce autophagic cell death typically induce GFP-LC3 staining patterns in breast cancer cells similar to those observed in this study with C-DIMs [
33,
37]. Bafilomycin blocks maturation of autophagosomes and in combination with C-DIMs did not inhibit or enhance their growth inhibitory effects in MDA-MB-231 and MDA-MB-453 cells (Figure ). However, bafilomycin alone increased accumulation of LC3b-II in both cell lines (Figure and ) and with the exception of DIM-C-pPhtBu (MDA-MB-453 cells), the C-DIM compounds further enhanced bafilomycin-induced LC3b-II levels, suggesting activation of autophagy in these cells.
An important difference between autophagy as a survival mechanism versus autophagic cell death involves the Atg5 and Atg6/Beclin 1 genes, which are upregulated in autophagic cell death [
41]. The anti-apoptotic protein Bcl-2 is also critically involved as a negative regulator of the induction of autophagy by Beclin 1 [
42]. Ceramide [
60], camptothecin [
61], and EB1089 [
37] induce autophagic cell death in breast cancer cells and all of these agents increase Beclin 1 protein expression. These observations are similar to the significant increase of Beclin 1 protein levels and Beclin 1/Bcl-2 ratios in MDA-MB-231 and MDA-MB-453 cells after treatment with C-DIMs (Figure and ) and also in tumors from mice bearing MDA-MB-231 cells as xenografts and treated with DIM-C-pPhC
6H
5 (Figure ). While further studies that explore autophagic flux and the actions of other autophagy inhibitors on C-DIM growth inhibition are warranted, these findings represent the first report to document the activation of an autophagic program in ER-negative breast cancer cells with C-DIMs.